Komori
Eucalia (286A) · InitiativeAdvancedLatest Earnings (2026-05-15): "Restated"

Development of Yucaria Touch With and Other Products

First written in FY2024. 2 of 4 entries say "Restated". Latest entry: 2026-05-15.

4entries
2years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024 – FY2025-H12025: 220252026: 22026
Same theme, other companies
Communication Support Terminals and AI Tools for Healthcare Professionals, Patients and FamiliesA theme 1 companies write about · 1 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. 2026-05-15RestatedEarnings

    「While addressing the structural challenges facing the healthcare and nursing care industries, including labor shortages and rising costs, we will continue to actively promote measures aimed at strengthening our business base and enhancing corporate value.」

    This disclosure contained no new information on individual development achievements, and direct progress beyond the existing DX and development policy was limited.
  2. FY2025AdvancedAnnual report

    「In the comprehensive healthcare management support business, we completed development of a communication tool, primarily a DX support tool, in which AI provides information, explanations and application assistance through dialogue and supports interactions between patients, their families and medical institutions.」

    Development of an AI tool supporting communication between patients, families and medical institutions was completed, and a system supporting the drafting of medical documents is also under development. R&D expenses were ¥54,086 thousand.
  3. FY2025-H1RestatedAnnual report

    「In the comprehensive healthcare support business, we have developed DX tools to reduce the workload of healthcare professionals, including "Yucaria Merge," which supports communication between hospitals and patients. As a result, R&D expenses in this business amounted to ¥48,114 thousand.」

    Development of DX tools such as "Yucaria Merge" to reduce healthcare professionals' workload continued. R&D expenses were ¥48,114 thousand.
  4. FY2024First statedAnnual report

    「In the comprehensive healthcare support business, we have been developing "Yucaria Touch With," a new bedside terminal for healthcare professionals that includes software development and is primarily intended as a DX support tool. Prototype development has been completed.」

    The new bedside terminal "Yucaria Touch With" for healthcare professionals has been developed and its prototype completed. An app supporting communication with patients' families is also under development.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Eucalia's next results are scheduled for 2026-11-13. Read the earnings preview It last moved in the Earnings of 2026-05-15: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.